Q3 EPS Forecast for Merit Medical Systems Lifted by Analyst

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Equities research analysts at Barrington Research boosted their Q3 2025 earnings per share (EPS) estimates for Merit Medical Systems in a research report issued to clients and investors on Wednesday, January 29th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings per share of $0.96 for the quarter, up from their previous forecast of $0.95. Barrington Research currently has a “Outperform” rating and a $115.00 target price on the stock. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.36 per share. Barrington Research also issued estimates for Merit Medical Systems’ Q4 2025 earnings at $0.94 EPS, FY2025 earnings at $3.82 EPS and FY2026 earnings at $4.30 EPS.

A number of other equities research analysts also recently weighed in on the company. StockNews.com downgraded Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Sunday, November 3rd. Robert W. Baird boosted their target price on shares of Merit Medical Systems from $107.00 to $109.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Piper Sandler restated an “overweight” rating and issued a $116.00 price target (up from $114.00) on shares of Merit Medical Systems in a research report on Wednesday. Wells Fargo & Company raised shares of Merit Medical Systems from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $103.00 to $120.00 in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group upped their target price on Merit Medical Systems from $127.00 to $128.00 and gave the company a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $109.80.

Merit Medical Systems Stock Down 0.5 %

Shares of Merit Medical Systems stock opened at $108.48 on Thursday. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average price of $101.27 and a 200 day moving average price of $96.96. Merit Medical Systems has a fifty-two week low of $70.70 and a fifty-two week high of $110.61. The firm has a market cap of $6.32 billion, a P/E ratio of 53.18, a P/E/G ratio of 2.34 and a beta of 0.85.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Wednesday, October 30th. The medical instruments supplier reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. The business had revenue of $339.85 million during the quarter, compared to the consensus estimate of $334.60 million. Merit Medical Systems had a net margin of 9.05% and a return on equity of 15.61%. The business’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 earnings per share.

Institutional Trading of Merit Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System increased its stake in shares of Merit Medical Systems by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,200 shares of the medical instruments supplier’s stock valued at $2,728,000 after acquiring an additional 100 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Merit Medical Systems by 1.0% in the 3rd quarter. Tidal Investments LLC now owns 10,398 shares of the medical instruments supplier’s stock valued at $1,028,000 after buying an additional 104 shares during the period. American Century Companies Inc. increased its position in shares of Merit Medical Systems by 2.9% in the 2nd quarter. American Century Companies Inc. now owns 4,216 shares of the medical instruments supplier’s stock valued at $362,000 after buying an additional 118 shares in the last quarter. Xponance Inc. raised its stake in Merit Medical Systems by 4.9% during the 2nd quarter. Xponance Inc. now owns 3,621 shares of the medical instruments supplier’s stock worth $311,000 after buying an additional 170 shares during the period. Finally, Glenmede Trust Co. NA lifted its holdings in Merit Medical Systems by 0.6% during the third quarter. Glenmede Trust Co. NA now owns 28,637 shares of the medical instruments supplier’s stock worth $2,830,000 after acquiring an additional 170 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Insider Buying and Selling at Merit Medical Systems

In related news, CFO Raul Jr. Parra sold 29,646 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $98.02, for a total transaction of $2,905,900.92. Following the completion of the sale, the chief financial officer now owns 16,361 shares in the company, valued at $1,603,705.22. This trade represents a 64.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director F. Ann Millner sold 12,500 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $101.55, for a total value of $1,269,375.00. Following the sale, the director now owns 32,391 shares in the company, valued at approximately $3,289,306.05. This trade represents a 27.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 3.70% of the company’s stock.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.